{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T17:17:13Z","timestamp":1793812633649,"version":"4.6.1"},"reference-count":196,"publisher":"Elsevier BV","issue":"42","license":[{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,11,25]],"date-time":"2020-11-25T00:00:00Z","timestamp":1606262400000},"content-version":"vor","delay-in-days":55,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["jbc.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Biological Chemistry"],"published-print":{"date-parts":[[2020,10]]},"DOI":"10.1074\/jbc.rev120.008387","type":"journal-article","created":{"date-parts":[[2020,8,12]],"date-time":"2020-08-12T21:45:10Z","timestamp":1597268710000},"page":"14379-14390","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":107,"title":["Sodium-glucose cotransporter-2 inhibitors: Understanding the mechanisms for therapeutic promise and persisting risks"],"prefix":"10.1016","volume":"295","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0748-8064","authenticated-orcid":false,"given":"Rachel J.","family":"Perry","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1529-5668","authenticated-orcid":false,"given":"Gerald I.","family":"Shulman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1074\/jbc.REV120.008387_bib1","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/j.devcel.2019.10.005","article-title":"Single-cell profiling reveals sex, lineage, and regional diversity in the mouse kidney","volume":"51","author":"Ransick","year":"2019","journal-title":"Dev. Cell"},{"key":"10.1074\/jbc.REV120.008387_bib2","doi-asserted-by":"crossref","first-page":"14669","DOI":"10.1074\/jbc.M212240200","article-title":"Cloning and characterization of a novel Na+-dependent glucose transporter (NaGLT1) in rat kidney","volume":"278","author":"Horiba","year":"2003","journal-title":"J. Biol. Chem"},{"key":"10.1074\/jbc.REV120.008387_bib3","doi-asserted-by":"crossref","first-page":"3324","DOI":"10.2337\/db13-0604","article-title":"Novel hypothesis to explain why SGLT2 inhibitors inhibit only 30\u201350% of filtered glucose load in humans","volume":"62","author":"Abdul-Ghani","year":"2013","journal-title":"Diabetes"},{"key":"10.1074\/jbc.REV120.008387_bib4","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1681\/ASN.2010030246","article-title":"SGLT2 mediates glucose reabsorption in the early proximal tubule","volume":"22","author":"Vallon","year":"2011","journal-title":"J. Am. Soc. Nephrol"},{"key":"10.1074\/jbc.REV120.008387_bib5","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1007\/s00125-016-4157-3","article-title":"Targeting renal glucose reabsorption to treat hyperglycaemia: the pleiotropic effects of SGLT2 inhibition","volume":"60","author":"Vallon","year":"2017","journal-title":"Diabetologia"},{"key":"10.1074\/jbc.REV120.008387_bib6","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1152\/physrev.00055.2009","article-title":"Biology of human sodium glucose transporters","volume":"91","author":"Wright","year":"2011","journal-title":"Physiol. Rev"},{"key":"10.1074\/jbc.REV120.008387_bib7","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1210\/er.2010-0029","article-title":"Role of sodium-glucose cotransporter 2 (SGLT 2) inhibitors in the treatment of type 2 diabetes","volume":"32","author":"Abdul-Ghani","year":"2011","journal-title":"Endocr. Rev"},{"key":"10.1074\/jbc.REV120.008387_bib8","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1007\/s40262-013-0104-3","article-title":"Clinical pharmacokinetics and pharmacodynamics of dapagliflozin, a selective inhibitor of sodium-glucose co-transporter type 2","volume":"53","author":"Kasichayanula","year":"2014","journal-title":"Clin. Pharmacokinet"},{"key":"10.1074\/jbc.REV120.008387_bib9","doi-asserted-by":"crossref","first-page":"31214","DOI":"10.1038\/srep31214","article-title":"Dapagliflozin stimulates glucagon secretion at high glucose: experiments and mathematical simulations of human A-cells","volume":"6","author":"Pedersen","year":"2016","journal-title":"Sci. Rep"},{"key":"10.1074\/jbc.REV120.008387_bib10","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1038\/clpt.2008.251","article-title":"Dapagliflozin, a novel SGLT2 inhibitor, induces dose-dependent glucosuria in healthy subjects","volume":"85","author":"Komoroski","year":"2009","journal-title":"Clin. Pharmacol. Ther"},{"key":"10.1074\/jbc.REV120.008387_bib11","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1111\/j.1463-1326.2011.01406.x","article-title":"Canagliflozin, a novel inhibitor of sodium glucose co-transporter 2, dose dependently reduces calculated renal threshold for glucose excretion and increases urinary glucose excretion in healthy subjects","volume":"13","author":"Sha","year":"2011","journal-title":"Diabetes Obes. Metab"},{"key":"10.1074\/jbc.REV120.008387_bib12","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1007\/BF03256922","article-title":"Effect of Ipragliflozin (ASP1941), a novel selective sodium-dependent glucose co-transporter 2 inhibitor, on urinary glucose excretion in healthy subjects","volume":"31","author":"Veltkamp","year":"2011","journal-title":"Clin. Drug Investig"},{"key":"10.1074\/jbc.REV120.008387_bib13","doi-asserted-by":"crossref","first-page":"E117","DOI":"10.1152\/ajpendo.00439.2012","article-title":"Improved glycemic control in mice lacking Sglt1 and Sglt2","volume":"304","author":"Powell","year":"2013","journal-title":"Am. J. Physiol. Endocrinol. Metab"},{"key":"10.1074\/jbc.REV120.008387_bib14","first-page":"178","article-title":"Analyse des phloridzins","volume":"15","author":"Petersen","year":"1835","journal-title":"Ann. Acad. Sci. Fr"},{"key":"10.1074\/jbc.REV120.008387_bib15","first-page":"110","article-title":"Observations sur les proprietes febrifuges de la phloridzine","volume":"75","author":"de Koninck","year":"1836","journal-title":"Soc. Med. Gand"},{"key":"10.1074\/jbc.REV120.008387_bib16","first-page":"531","article-title":"Ueber kunstlichen diabetes","volume":"xxii","author":"von Mering","year":"1886","journal-title":"Centralbl. Med. Wiss"},{"key":"10.1074\/jbc.REV120.008387_bib17","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1152\/ajplegacy.1932.100.2.301","article-title":"The excretion of urine in the dog. I. The use of non-metabolized sugars in the measurement of glomerular filtrate","volume":"100","author":"Jolliffe","year":"1932","journal-title":"Am. J. Physiol"},{"key":"10.1074\/jbc.REV120.008387_bib18","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1172\/JCI100559","article-title":"The action of phlorizin on the excretion of glucose, xylose, sucrose, creatinine and urea by man","volume":"12","author":"Chasis","year":"1933","journal-title":"J. Clin. Invest"},{"key":"10.1074\/jbc.REV120.008387_bib19","first-page":"379","article-title":"The bark of the apple root, phlorizin, reduces diabetic hyperglycemia","author":"Achard","year":"1899","journal-title":"Soc. Medic. Des Hospitaux"},{"key":"10.1074\/jbc.REV120.008387_bib20","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/0006-3002(62)90543-7","article-title":"Phlorizin as a competitive inhibitor of the active transport of sugars by hamster small intestine, in vitro","volume":"56","author":"Alvarado","year":"1962","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1074\/jbc.REV120.008387_bib21","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1152\/ajplegacy.1973.224.3.552","article-title":"Reevaluation of renal tubular glucose transport inhibition by phlorizin analogs","volume":"224","author":"Vick","year":"1973","journal-title":"Am. J. Physiol"},{"key":"10.1074\/jbc.REV120.008387_bib22","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/0005-2736(92)90144-B","article-title":"Baculovirus-mediated expression of the Na+\/glucose cotransporter in Sf9 cells","volume":"1104","author":"Smith","year":"1992","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1074\/jbc.REV120.008387_bib23","doi-asserted-by":"crossref","first-page":"27099","DOI":"10.1074\/jbc.270.45.27099","article-title":"Kinetics of steady-state currents and charge movements associated with the rat Na+\/glucose cotransporter","volume":"270","author":"Panayotova-Heiermann","year":"1995","journal-title":"J. Biol. Chem"},{"key":"10.1074\/jbc.REV120.008387_bib24","doi-asserted-by":"crossref","first-page":"273","DOI":"10.2337\/db19-0138","article-title":"Glucolipotoxicity, \u03b2-cells, and diabetes: the emperor has no clothes","volume":"69","author":"Weir","year":"2020","journal-title":"Diabetes"},{"key":"10.1074\/jbc.REV120.008387_bib25","doi-asserted-by":"crossref","first-page":"1514","DOI":"10.1016\/j.jmb.2019.09.016","article-title":"Recent insights into mechanisms of \u03b2-cell lipo- and glucolipotoxicity in type 2 diabetes","volume":"432","author":"Lytrivi","year":"2020","journal-title":"J. Mol. Biol"},{"key":"10.1074\/jbc.REV120.008387_bib26","doi-asserted-by":"crossref","first-page":"1510","DOI":"10.1172\/JCI112981","article-title":"Correction of hyperglycemia with phlorizin normalizes tissue sensitivity to insulin in diabetic rats","volume":"79","author":"Rossetti","year":"1987","journal-title":"J. Clin. Invest"},{"key":"10.1074\/jbc.REV120.008387_bib27","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1172\/JCI113157","article-title":"Effect of chronic hyperglycemia on in vivo insulin secretion in partially pancreatectomized rats","volume":"80","author":"Rossetti","year":"1987","journal-title":"J. Clin. Invest"},{"key":"10.1074\/jbc.REV120.008387_bib28","doi-asserted-by":"crossref","first-page":"890","DOI":"10.2337\/db10-1328","article-title":"SGLT2 deletion improves glucose homeostasis and preserves pancreatic beta-cell function","volume":"60","author":"Jurczak","year":"2011","journal-title":"Diabetes"},{"key":"10.1074\/jbc.REV120.008387_bib29","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1080\/19382014.2018.1503027","article-title":"SGLT2 knockout prevents hyperglycemia and is associated with reduced pancreatic \u03b2-cell death in genetically obese mice","volume":"10","author":"Jurczak","year":"2018","journal-title":"Islets"},{"key":"10.1074\/jbc.REV120.008387_bib30","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/0005-2736(75)90028-0","article-title":"Inhibition of glucose transport into brain by phlorizin, phloretin and glucose analogues","volume":"406","author":"Betz","year":"1975","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1074\/jbc.REV120.008387_bib31","doi-asserted-by":"crossref","first-page":"C1277","DOI":"10.1152\/ajpcell.00296.2010","article-title":"Functional expression of SGLTs in rat brain","volume":"299","author":"Yu","year":"2010","journal-title":"Am. J. Physiol. Cell Physiol"},{"key":"10.1074\/jbc.REV120.008387_bib32","doi-asserted-by":"crossref","first-page":"C240","DOI":"10.1152\/ajpcell.00317.2012","article-title":"Regional distribution of SGLT activity in rat brain in vivo","volume":"304","author":"Yu","year":"2013","journal-title":"Am. J. Physiol. Cell Physiol"},{"key":"10.1074\/jbc.REV120.008387_bib33","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1046\/j.1471-4159.1998.70020772.x","article-title":"Na+-dependent and phlorizin-inhibitable transport of glucose and cycasin in brain endothelial cells","volume":"70","author":"Matsuoka","year":"1998","journal-title":"J. Neurochem"},{"key":"10.1074\/jbc.REV120.008387_bib34","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1038\/nrneph.2010.38","article-title":"Renal glucose transporters: novel targets for hyperglycemia management","volume":"6","author":"Mather","year":"2010","journal-title":"Nat. Rev. Nephrol"},{"key":"10.1074\/jbc.REV120.008387_bib35","doi-asserted-by":"crossref","first-page":"3227","DOI":"10.1093\/jn\/131.12.3227","article-title":"Bioavailability of phloretin and phloridzin in rats","volume":"131","author":"Crespy","year":"2001","journal-title":"J. Nutr"},{"key":"10.1074\/jbc.REV120.008387_bib36","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1039\/C8FO02242A","article-title":"Comparative oral and intravenous pharmacokinetics of phlorizin in rats having type 2 diabetes and in normal rats based on phase II metabolism","volume":"10","author":"Wang","year":"2019","journal-title":"Food Funct"},{"key":"10.1074\/jbc.REV120.008387_bib37","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1007\/s13300-010-0006-4","article-title":"Quantitative PCR tissue expression profiling of the human SGLT2 gene and related family members","volume":"1","author":"Chen","year":"2010","journal-title":"Diabetes Ther"},{"key":"10.1074\/jbc.REV120.008387_bib38","doi-asserted-by":"crossref","first-page":"262","DOI":"10.7326\/0003-4819-159-4-201308200-00007","article-title":"Sodium-glucose cotransporter 2 inhibitors for type 2 diabetes: a systematic review and meta-analysis","volume":"159","author":"Vasilakou","year":"2013","journal-title":"Ann. Intern. Med"},{"key":"10.1074\/jbc.REV120.008387_bib39","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1056\/NEJMoa1611925","article-title":"Canagliflozin and cardiovascular and renal events in type 2 diabetes","volume":"377","author":"Neal","year":"2017","journal-title":"N. Engl. J. Med"},{"key":"10.1074\/jbc.REV120.008387_bib40","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","article-title":"Canagliflozin and renal outcomes in type 2 diabetes and nephropathy","volume":"380","author":"Perkovic","year":"2019","journal-title":"N. Engl. J. Med"},{"key":"10.1074\/jbc.REV120.008387_bib41","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1056\/NEJMoa1812389","article-title":"Dapagliflozin and cardiovascular outcomes in type 2 diabetes","volume":"380","author":"Wiviott","year":"2019","journal-title":"N. Engl. J. Med"},{"key":"10.1074\/jbc.REV120.008387_bib42","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.1111\/dom.14075","article-title":"Sodium-glucose co-transporter-2 inhibitors and the risk of diabetic ketoacidosis in patients with type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials","volume":"22","author":"Liu","year":"2020","journal-title":"Diabetes Obes. Metab"},{"key":"10.1074\/jbc.REV120.008387_bib43","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.2337\/dc15-0843","article-title":"Euglycemic diabetic ketoacidosis: a potential complication of treatment with sodium-glucose cotransporter 2 inhibition","volume":"38","author":"Peters","year":"2015","journal-title":"Diabetes Care"},{"key":"10.1074\/jbc.REV120.008387_bib44","doi-asserted-by":"crossref","first-page":"e2924","DOI":"10.1002\/dmrr.2924","article-title":"Ketoacidosis associated with SGLT2 inhibitor treatment: analysis of FAERS data","volume":"33","author":"Blau","year":"2017","journal-title":"Diabetes Metab. Res. Rev"},{"key":"10.1074\/jbc.REV120.008387_bib45","doi-asserted-by":"crossref","first-page":"362","DOI":"10.15585\/mmwr.mm6712a3","article-title":"Trends in diabetic ketoacidosis hospitalizations and in-hospital mortality\u2014United States, 2000\u20132014","volume":"67","author":"Benoit","year":"2018","journal-title":"MMWR Morb. Mortal. Wkly. Rep"},{"key":"10.1074\/jbc.REV120.008387_bib46","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/j.jcjd.2017.05.004","article-title":"Insights into the recognition and management of SGLT2-inhibitor-associated ketoacidosis: it's not just euglycemic diabetic ketoacidosis","volume":"41","author":"Dizon","year":"2017","journal-title":"Can. J. Diabetes"},{"key":"10.1074\/jbc.REV120.008387_bib47","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/0002-9343(73)90083-1","article-title":"Hyperglucagonemia in diabetic ketoacidosis: its prevalence and significance","volume":"54","author":"M\u00fcller","year":"1973","journal-title":"Am. J. Med"},{"key":"10.1074\/jbc.REV120.008387_bib48","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1001\/archinte.1977.03630160050012","article-title":"Role of glucagon in diabetes","volume":"137","author":"Unger","year":"1977","journal-title":"Arch. Intern. Med"},{"key":"10.1074\/jbc.REV120.008387_bib49","doi-asserted-by":"crossref","first-page":"926","DOI":"10.2337\/diab.29.11.926","article-title":"Effects of acute insulin deficiency on glucose and ketone body turnover in man: evidence for the primacy of overproduction of glucose and ketone bodies in the genesis of diabetic ketoacidosis","volume":"29","author":"Miles","year":"1980","journal-title":"Diabetes"},{"key":"10.1074\/jbc.REV120.008387_bib50","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1172\/JCI72227","article-title":"Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients","volume":"124","author":"Ferrannini","year":"2014","journal-title":"J. Clin. Invest"},{"key":"10.1074\/jbc.REV120.008387_bib51","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1172\/JCI70704","article-title":"Dapagliflozin improves muscle insulin sensitivity but enhances endogenous glucose production","volume":"124","author":"Merovci","year":"2014","journal-title":"J. Clin. Invest"},{"key":"10.1074\/jbc.REV120.008387_bib52","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.2337\/db17-1278","article-title":"Endogenous glucose production and hormonal changes in response to canagliflozin and liraglutide combination therapy","volume":"67","author":"Martinez","year":"2018","journal-title":"Diabetes"},{"key":"10.1074\/jbc.REV120.008387_bib53","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1038\/s41467-019-08466-w","article-title":"Dehydration and insulinopenia are necessary and sufficient for euglycemic ketoacidosis in SGLT2 inhibitor-treated rats","volume":"10","author":"Perry","year":"2019","journal-title":"Nat. Commun"},{"key":"10.1074\/jbc.REV120.008387_bib54","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1038\/nm.3828","article-title":"Inhibition of the glucose transporter SGLT2 with dapagliflozin in pancreatic \u03b1 cells triggers glucagon secretion","volume":"21","author":"Bonner","year":"2015","journal-title":"Nat. Med"},{"key":"10.1074\/jbc.REV120.008387_bib55","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.molmet.2018.10.009","article-title":"SGLT1 in pancreatic \u03b1 cells regulates glucagon secretion in mice, possibly explaining the distinct effects of SGLT2 inhibitors on plasma glucagon levels","volume":"19","author":"Suga","year":"2019","journal-title":"Mol. Metab"},{"key":"10.1074\/jbc.REV120.008387_bib56","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/j.cmet.2013.08.004","article-title":"Leptin engages a hypothalamic neurocircuitry to permit survival in the absence of insulin","volume":"18","author":"Fujikawa","year":"2013","journal-title":"Cell Metab"},{"key":"10.1074\/jbc.REV120.008387_bib57","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1038\/s41586-020-2074-6","article-title":"Glucagon stimulates gluconeogenesis by INSP3R1-mediated hepatic lipolysis","volume":"579","author":"Perry","year":"2020","journal-title":"Nature"},{"key":"10.1074\/jbc.REV120.008387_bib58","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1016\/0002-9343(66)90151-3","article-title":"Gluconeogenesis in the perfused liver. The effects of fasting, alloxan diabetes, glucagon, epinephrine, adenosine 3',5'-monophosphate and insulin","volume":"40","author":"Exton","year":"1966","journal-title":"Am. J. Med"},{"key":"10.1074\/jbc.REV120.008387_bib59","first-page":"181","article-title":"The stimulation of gluconeogenesis from lactate by epinephrine, glucagon, cyclic 3',5'-adenylate in the perfused rat liver","volume":"18","author":"Exton","year":"1966","journal-title":"Pharmacol. Rev"},{"key":"10.1074\/jbc.REV120.008387_bib60","doi-asserted-by":"crossref","first-page":"4189","DOI":"10.1016\/S0021-9258(18)93242-4","article-title":"Control of gluconeogenesis in liver. II. Effects of glucagon, catecholamines, and adenosine 3',5'-monophosphate on gluconeogenesis in the perfused rat liver","volume":"243","author":"Exton","year":"1968","journal-title":"J. Biol. Chem"},{"key":"10.1074\/jbc.REV120.008387_bib61","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1016\/S0021-9258(19)52762-4","article-title":"Influence of insulin preparations on glycogenolysis in liver slices","volume":"172","author":"Sutherland","year":"1948","journal-title":"J. Biol. Chem"},{"key":"10.1074\/jbc.REV120.008387_bib62","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1210\/endo-74-6-930","article-title":"Relative potency of glucagon and epinephrine as hepatic glycogenolytic agents: studies with the isolated perfused rat liver","volume":"74","author":"Sokal","year":"1964","journal-title":"Endocrinology"},{"key":"10.1074\/jbc.REV120.008387_bib63","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/0304-4165(74)90142-1","article-title":"Activation of glycogenolysis in perfused rat livers by glucagon and metabolic inhibitors","volume":"362","author":"Jakob","year":"1974","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1074\/jbc.REV120.008387_bib64","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1016\/j.diabet.2017.04.002","article-title":"Dapagliflozin modulates glucagon secretion in an SGLT2-independent manner in murine alpha cells","volume":"43","author":"Solini","year":"2017","journal-title":"Diabetes Metab"},{"key":"10.1074\/jbc.REV120.008387_bib65","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1007\/s00125-019-4849-6","article-title":"No direct effect of SGLT2 activity on glucagon secretion","volume":"62","author":"Kuhre","year":"2019","journal-title":"Diabetologia"},{"key":"10.1074\/jbc.REV120.008387_bib66","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1038\/s41467-018-08193-8","article-title":"Insulin inhibits glucagon release by SGLT2-induced stimulation of somatostatin secretion","volume":"10","author":"Vergari","year":"2019","journal-title":"Nat. Commun"},{"key":"10.1074\/jbc.REV120.008387_bib67","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1016\/j.cmet.2018.10.003","article-title":"Dysregulation of glucagon secretion by hyperglycemia-induced sodium-dependent reduction of ATP production","volume":"29","author":"Knudsen","year":"2019","journal-title":"Cell Metab"},{"key":"10.1074\/jbc.REV120.008387_bib68","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1172\/JCI108364","article-title":"Effects of physiologic levels of glucagon and growth hormone on human carbohydrate and lipid metabolism: studies involving administration of exogenous hormone during suppression of endogenous hormone secretion with somatostatin","volume":"57","author":"Gerich","year":"1976","journal-title":"J. Clin. Invest"},{"key":"10.1074\/jbc.REV120.008387_bib69","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1210\/jcem-70-2-410","article-title":"Does glucagon increase plasma free fatty acid concentration in humans with normal glucose tolerance?","volume":"70","author":"Wu","year":"1990","journal-title":"J. Clin. Endocrinol. Metab"},{"key":"10.1074\/jbc.REV120.008387_bib70","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1210\/jcem-72-2-308","article-title":"Effects of glucagon on free fatty acid metabolism in humans","volume":"72","author":"Jensen","year":"1991","journal-title":"J. Clin. Endocrinol. Metab"},{"key":"10.1074\/jbc.REV120.008387_bib71","first-page":"6","article-title":"Glucagon does not increase plasma free fatty acid and glycerol concentrations in patients with noninsulin-dependent diabetes mellitus","volume":"77","author":"Jeng","year":"1993","journal-title":"J. Clin. Endocrinol. Metab"},{"key":"10.1074\/jbc.REV120.008387_bib72","first-page":"2085","article-title":"Physiological levels of glucagon do not influence lipolysis in abdominal adipose tissue as assessed by microdialysis","volume":"86","author":"Gravholt","year":"2001","journal-title":"J. Clin. Endocrinol. Metab"},{"key":"10.1074\/jbc.REV120.008387_bib73","first-page":"1229","article-title":"Action of glucagon and glucagon-like peptide-1-(7-36) amide on lipolysis in human subcutaneous adipose tissue and skeletal muscle in vivo","volume":"86","author":"Bertin","year":"2001","journal-title":"J. Clin. Endocrinol. Metab"},{"key":"10.1074\/jbc.REV120.008387_bib74","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1016\/S0021-9258(18)64236-X","article-title":"Effect of glucagon on the metabolism of adipose tissue","volume":"236","author":"Hagen","year":"1961","journal-title":"J. Biol. Chem"},{"key":"10.1074\/jbc.REV120.008387_bib75","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1172\/JCI88477","article-title":"Mechanism for leptin's acute insulin-independent effect to reverse diabetic ketoacidosis","volume":"127","author":"Perry","year":"2017","journal-title":"J. Clin. Invest"},{"key":"10.1074\/jbc.REV120.008387_bib76","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1038\/nm.3579","article-title":"Leptin reverses diabetes by suppression of the hypothalamic-pituitary-adrenal axis","volume":"20","author":"Perry","year":"2014","journal-title":"Nat. Med"},{"key":"10.1074\/jbc.REV120.008387_bib77","doi-asserted-by":"crossref","first-page":"1554","DOI":"10.1172\/JCI110911","article-title":"Effects of free fatty acid availability, glucagon excess, and insulin deficiency on ketone body production in postabsorptive man","volume":"71","author":"Miles","year":"1983","journal-title":"J. Clin. Invest"},{"key":"10.1074\/jbc.REV120.008387_bib78","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1007\/s00125-018-4785-x","article-title":"Substrate metabolism, hormone and cytokine levels and adipose tissue signalling in individuals with type 1 diabetes after insulin withdrawal and subsequent insulin therapy to model the initiating steps of ketoacidosis","volume":"62","author":"Voss","year":"2019","journal-title":"Diabetologia"},{"key":"10.1074\/jbc.REV120.008387_bib79","first-page":"E154","article-title":"A critical evaluation of mass isotopomer distribution analysis of gluconeogenesis in vivo","volume":"277","author":"Previs","year":"1999","journal-title":"Am. J. Physiol"},{"key":"10.1074\/jbc.REV120.008387_bib80","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/0026-0495(76)90091-3","article-title":"Gluconeogenesis from glycerol at rest and during exercise in normal, diabetic, and methylprednisolone-treated dogs","volume":"25","author":"Shaw","year":"1976","journal-title":"Metabolism"},{"key":"10.1074\/jbc.REV120.008387_bib81","first-page":"E1110","article-title":"Glycerol production and utilization in humans: sites and quantitation","volume":"271","author":"Landau","year":"1996","journal-title":"Am. J. Physiol"},{"key":"10.1074\/jbc.REV120.008387_bib82","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1016\/S0021-9258(17)45212-4","article-title":"Pyruvate carboxylase. IV. Partial reactions and the locus of activation by acetyl coenzyme A","volume":"240","author":"Scrutton","year":"1965","journal-title":"J. Biol. Chem"},{"key":"10.1074\/jbc.REV120.008387_bib83","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/S0065-2571(64)80005-4","article-title":"A possible role for acetyl CoA in the control of gluconeogenesis","volume":"2","author":"Utter","year":"1964","journal-title":"Adv. Enzyme Regul"},{"key":"10.1074\/jbc.REV120.008387_bib84","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1016\/j.cell.2015.01.012","article-title":"Hepatic acetyl CoA links adipose tissue inflammation to hepatic insulin resistance and type 2 diabetes","volume":"160","author":"Perry","year":"2015","journal-title":"Cell"},{"key":"10.1074\/jbc.REV120.008387_bib85","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1186\/1475-2840-13-65","volume":"13","author":"Kaku","year":"2014","journal-title":"Cardiovasc. Diabetol"},{"key":"10.1074\/jbc.REV120.008387_bib86","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1042\/bj1380001","article-title":"Regulation of glucose and ketone-body metabolism in brain of anaesthetized rats","volume":"138","author":"Ruderman","year":"1974","journal-title":"Biochem. J"},{"key":"10.1074\/jbc.REV120.008387_bib87","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.ejphar.2014.01.040","article-title":"SGLT2 selective inhibitor ipragliflozin reduces body fat mass by increasing fatty acid oxidation in high-fat diet-induced obese rats","volume":"727","author":"Yokono","year":"2014","journal-title":"Eur. J. Pharmacol"},{"key":"10.1074\/jbc.REV120.008387_bib88","doi-asserted-by":"crossref","first-page":"2849","DOI":"10.1210\/jc.2015-1884","article-title":"SGLT2 inhibitors may predispose to ketoacidosis","volume":"100","author":"Taylor","year":"2015","journal-title":"J. Clin. Endocrinol. Metab"},{"key":"10.1074\/jbc.REV120.008387_bib89","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.2337\/dc19-2177","article-title":"Increase in endogenous glucose production with SGLT2 inhibition is unchanged by renal denervation and correlates strongly with the increase in urinary glucose excretion","volume":"43","author":"Solis-Herrera","year":"2020","journal-title":"Diabetes Care"},{"key":"10.1074\/jbc.REV120.008387_bib90","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.2337\/db16-1410","article-title":"Correcting postprandial hyperglycemia in Zucker diabetic fatty rats with an SGLT2 inhibitor restores glucose effectiveness in the liver and reduces insulin resistance in skeletal muscle","volume":"66","author":"O'Brien","year":"2017","journal-title":"Diabetes"},{"key":"10.1074\/jbc.REV120.008387_bib91","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.2337\/db15-1356","article-title":"Shift to fatty substrate utilization in response to sodium-glucose cotransporter 2 inhibition in subjects without diabetes and patients with type 2 diabetes","volume":"65","author":"Ferrannini","year":"2016","journal-title":"Diabetes"},{"key":"10.1074\/jbc.REV120.008387_bib92","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1007\/s00125-015-3845-8","article-title":"Metabolic consequences of acute and chronic empagliflozin administration in treatment-naive and metformin pretreated patients with type 2 diabetes","volume":"59","author":"Muscelli","year":"2016","journal-title":"Diabetologia"},{"key":"10.1074\/jbc.REV120.008387_bib93","doi-asserted-by":"crossref","first-page":"1260419","DOI":"10.1126\/science.1260419","article-title":"Proteomics: tissue-based map of the human proteome","volume":"347","author":"Uhl\u00e9n","year":"2015","journal-title":"Science"},{"key":"10.1074\/jbc.REV120.008387_bib94","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1210\/jc.2018-00969","article-title":"Glucagon levels during short-term SGLT2 inhibition are largely regulated by glucose changes in patients with type 2 diabetes","volume":"104","author":"Lundkvist","year":"2019","journal-title":"J. Clin. Endocrinol. Metab"},{"key":"10.1074\/jbc.REV120.008387_bib95","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.1172\/JCI117150","article-title":"Ventromedial hypothalamic lesions in rats suppress counterregulatory responses to hypoglycemia","volume":"93","author":"Borg","year":"1994","journal-title":"J. Clin. Invest"},{"key":"10.1074\/jbc.REV120.008387_bib96","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1172\/JCI119165","article-title":"Local ventromedial hypothalamus glucose perfusion blocks counterregulation during systemic hypoglycemia in awake rats","volume":"99","author":"Borg","year":"1997","journal-title":"J. Clin. Invest"},{"key":"10.1074\/jbc.REV120.008387_bib97","doi-asserted-by":"crossref","first-page":"681","DOI":"10.2337\/db19-0770","article-title":"Evidence against an important role of plasma insulin and glucagon concentrations in the increase in EGP caused by SGLT2 inhibitors","volume":"69","author":"Alatrach","year":"2020","journal-title":"Diabetes"},{"key":"10.1074\/jbc.REV120.008387_bib98","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1002\/phar.1881","article-title":"SGLT2 Inhibitors: a systematic review of diabetic ketoacidosis and related risk factors in the primary literature","volume":"37","author":"Burke","year":"2017","journal-title":"Pharmacotherapy"},{"key":"10.1074\/jbc.REV120.008387_bib99","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1007\/s40261-019-00794-5","article-title":"Adverse drug reaction profile of SGLT2 inhibitor-associated diabetic ketosis\/ketoacidosis in Singapore and their precipitating factors","volume":"39","author":"Limenta","year":"2019","journal-title":"Clin. Drug Investig"},{"key":"10.1074\/jbc.REV120.008387_bib100","doi-asserted-by":"crossref","first-page":"1680","DOI":"10.2337\/dc15-1251","article-title":"Diabetic ketoacidosis and related events in the canagliflozin type 2 diabetes clinical program","volume":"38","author":"Erondu","year":"2015","journal-title":"Diabetes Care"},{"key":"10.1074\/jbc.REV120.008387_bib101","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/j.jacc.2017.11.022","article-title":"Cardiovascular mortality reduction with empagliflozin in patients with type 2 diabetes and cardiovascular disease","volume":"71","author":"Fitchett","year":"2018","journal-title":"J. Am. Coll. Cardiol"},{"key":"10.1074\/jbc.REV120.008387_bib102","doi-asserted-by":"crossref","first-page":"e42","DOI":"10.2337\/dc18-1959","article-title":"Empagliflozin and cardiovascular outcomes in patients with type 2 diabetes and left ventricular hypertrophy: a subanalysis of the EMPA-REG OUTCOME trial","volume":"42","author":"Verma","year":"2019","journal-title":"Diabetes Care"},{"key":"10.1074\/jbc.REV120.008387_bib103","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes","volume":"373","author":"Zinman","year":"2015","journal-title":"N. Engl. J. Med"},{"key":"10.1074\/jbc.REV120.008387_bib104","doi-asserted-by":"crossref","first-page":"e002922","DOI":"10.1161\/CIRCHEARTFAILURE.115.002922","article-title":"Fluid volume overload and congestion in heart failure: time to reconsider pathophysiology and how volume is assessed","volume":"9","author":"Miller","year":"2016","journal-title":"Circ. Heart Fail"},{"key":"10.1074\/jbc.REV120.008387_bib105","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/j.jacc.2016.05.043","article-title":"High-output heart failure: a 15-year experience","volume":"68","author":"Reddy","year":"2016","journal-title":"J. Am. Coll. Cardiol"},{"key":"10.1074\/jbc.REV120.008387_bib106","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","article-title":"Dapagliflozin in patients with heart failure and reduced ejection fraction","volume":"381","author":"McMurray","year":"2019","journal-title":"N. Engl. J. Med"},{"key":"10.1074\/jbc.REV120.008387_bib107","doi-asserted-by":"crossref","first-page":"356","DOI":"10.2337\/dc17-1096","article-title":"How does empagliflozin reduce cardiovascular mortality? Insights from a mediation analysis of the EMPA-REG OUTCOME trial","volume":"41","author":"Inzucchi","year":"2018","journal-title":"Diabetes Care"},{"key":"10.1074\/jbc.REV120.008387_bib108","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1161\/CIRCULATIONAHA.117.032038","article-title":"Canagliflozin for primary and secondary prevention of cardiovascular events: results from the CANVAS Program (Canagliflozin Cardiovascular Assessment Study)","volume":"137","author":"Mahaffey","year":"2018","journal-title":"Circulation"},{"key":"10.1074\/jbc.REV120.008387_bib109","doi-asserted-by":"crossref","first-page":"2528","DOI":"10.1161\/CIRCULATIONAHA.119.040130","article-title":"Effect of dapagliflozin on heart failure and mortality in type 2 diabetes mellitus","volume":"139","author":"Kato","year":"2019","journal-title":"Circulation"},{"key":"10.1074\/jbc.REV120.008387_bib110","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1161\/CIRCULATIONAHA.119.042929","article-title":"Dapagliflozin effects on biomarkers, symptoms, and functional status in patients with heart failure with reduced ejection fraction: the DEFINE-HF trial","volume":"140","author":"Nassif","year":"2019","journal-title":"Circulation"},{"key":"10.1074\/jbc.REV120.008387_bib111","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1186\/s12933-018-0717-9","article-title":"Effect of canagliflozin on left ventricular diastolic function in patients with type 2 diabetes","volume":"17","author":"Matsutani","year":"2018","journal-title":"Cardiovasc. Diabetol"},{"key":"10.1074\/jbc.REV120.008387_bib112","doi-asserted-by":"crossref","first-page":"k119","DOI":"10.1136\/bmj.k119","article-title":"Cardiovascular outcomes associated with canagliflozin versus other non-gliflozin antidiabetic drugs: population based cohort study","volume":"360","author":"Patorno","year":"2018","journal-title":"BMJ"},{"key":"10.1074\/jbc.REV120.008387_bib113","doi-asserted-by":"crossref","first-page":"1904","DOI":"10.1161\/CIRCULATIONAHA.118.035759","article-title":"Improvement in cardiovascular outcomes with empagliflozin is independent of glycemic control","volume":"138","author":"Inzucchi","year":"2018","journal-title":"Circulation"},{"key":"10.1074\/jbc.REV120.008387_bib114","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1136\/heartjnl-2013-305294","article-title":"Prospective development and validation of a model to predict heart failure hospitalisation","volume":"100","author":"Cubbon","year":"2014","journal-title":"Heart"},{"key":"10.1074\/jbc.REV120.008387_bib115","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1056\/NEJMoa1501352","article-title":"Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes","volume":"373","author":"Green","year":"2015","journal-title":"N. Engl. J. Med"},{"key":"10.1074\/jbc.REV120.008387_bib116","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1002\/ejhf.146","article-title":"Impaired fasting glucose: a predictor of reduced survival in patients with heart failure","volume":"16","author":"Gotsman","year":"2014","journal-title":"Eur. J. Heart Fail"},{"key":"10.1074\/jbc.REV120.008387_bib117","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1111\/dom.14015","article-title":"Empagliflozin reduces the risk of mortality and hospitalization for heart failure across thrombolysis in myocardial infarction risk score for heart failure in diabetes categories: post hoc analysis of the EMPA-REG OUTCOME trial","volume":"22","author":"Verma","year":"2020","journal-title":"Diabetes Obes. Metab"},{"key":"10.1074\/jbc.REV120.008387_bib118","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1056\/NEJMc1706292","article-title":"Mortality and cardiovascular disease in type 1 and type 2 diabetes","volume":"377","author":"Rawshani","year":"2017","journal-title":"N. Engl. J. Med"},{"key":"10.1074\/jbc.REV120.008387_bib119","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1016\/j.amjcard.2012.12.054","article-title":"U-shape association between hemoglobin A1c and late mortality in patients with heart failure after cardiac surgery","volume":"111","author":"Engoren","year":"2013","journal-title":"Am. J. Cardiol"},{"key":"10.1074\/jbc.REV120.008387_bib120","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.2337\/db10-0165","article-title":"The association of hemoglobin a1c with incident heart failure among people without diabetes: the atherosclerosis risk in communities study","volume":"59","author":"Matsushita","year":"2010","journal-title":"Diabetes"},{"key":"10.1074\/jbc.REV120.008387_bib121","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1161\/CIRCULATIONAHA.119.044183","article-title":"Effect of dapagliflozin on atrial fibrillation in patients with type 2 diabetes mellitus: insights from the DECLARE-TIMI 58 trial","volume":"141","author":"Zelniker","year":"2020","journal-title":"Circulation"},{"key":"10.1074\/jbc.REV120.008387_bib122","doi-asserted-by":"crossref","first-page":"1530","DOI":"10.2337\/dc20-0227","article-title":"Using the BRAVO risk engine to predict cardiovascular outcomes in clinical trials with sodium-glucose transporter 2 inhibitors","volume":"43","author":"Shao","year":"2020","journal-title":"Diabetes Care"},{"key":"10.1074\/jbc.REV120.008387_bib123","doi-asserted-by":"crossref","first-page":"104781","DOI":"10.1016\/j.phrs.2020.104781","article-title":"Amelioration of diastolic dysfunction by dapagliflozin in a non-diabetic model involves coronary endothelium","volume":"157","author":"Cappetta","year":"2020","journal-title":"Pharmacol. Res"},{"key":"10.1074\/jbc.REV120.008387_bib124","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.lfs.2019.05.051","article-title":"Effect of ipragliflozin, an SGLT2 inhibitor, on cardiac histopathological changes in a non-diabetic rat model of cardiomyopathy","volume":"230","author":"Takasu","year":"2019","journal-title":"Life Sci"},{"key":"10.1074\/jbc.REV120.008387_bib125","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1186\/s12967-019-1881-8","article-title":"Acute canagliflozin treatment protects against in vivo myocardial ischemia-reperfusion injury in non-diabetic male rats and enhances endothelium-dependent vasorelaxation","volume":"17","author":"Sayour","year":"2019","journal-title":"J. Transl. Med"},{"key":"10.1074\/jbc.REV120.008387_bib126","doi-asserted-by":"crossref","first-page":"2302-PUB","DOI":"10.2337\/db18-2302-PUB","article-title":"Meta-analysis of HbA1c-lowering efficacy of dipeptidyl peptidase-4 inhibitors in combination with insulin in T2DM patients","volume":"67","author":"Yang","year":"2018","journal-title":"Diabetes"},{"key":"10.1074\/jbc.REV120.008387_bib127","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1111\/dom.12174","article-title":"Efficacy and safety of dipeptidyl peptidase-4 inhibitors and metformin as initial combination therapy and as monotherapy in patients with type 2 diabetes mellitus: a meta-analysis","volume":"16","author":"Wu","year":"2014","journal-title":"Diabetes Obes. Metab"},{"key":"10.1074\/jbc.REV120.008387_bib128","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.2337\/dc09-1727","article-title":"The effect of oral antidiabetic agents on A1C levels: a systematic review and meta-analysis","volume":"33","author":"Sherifali","year":"2010","journal-title":"Diabetes Care"},{"key":"10.1074\/jbc.REV120.008387_bib129","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/s12933-020-0990-2","article-title":"Favorable pleiotropic effects of sodium glucose cotransporter 2 inhibitors: head-to-head comparisons with dipeptidyl peptidase-4 inhibitors in type 2 diabetes patients","volume":"19","author":"Shao","year":"2020","journal-title":"Cardiovasc. Diabetol"},{"key":"10.1074\/jbc.REV120.008387_bib130","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1007\/s00125-013-2856-6","article-title":"Estimating the effect of sulfonylurea on HbA1c in diabetes: a systematic review and meta-analysis","volume":"56","author":"Hirst","year":"2013","journal-title":"Diabetologia"},{"key":"10.1074\/jbc.REV120.008387_bib131","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1177\/2042018814559725","article-title":"GLP-1 receptor agonists: a review of head-to-head clinical studies","volume":"6","author":"Trujillo","year":"2015","journal-title":"Ther. Adv. Endocrinol. Metab"},{"key":"10.1074\/jbc.REV120.008387_bib132","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1007\/s13300-016-0155-1","article-title":"A network meta-analysis comparing exenatide once weekly with other GLP-1 receptor agonists for the treatment of type 2 diabetes mellitus","volume":"7","author":"Kayaniyil","year":"2016","journal-title":"Diabetes Ther"},{"key":"10.1074\/jbc.REV120.008387_bib133","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1111\/jvp.12467","article-title":"Effects of the sodium-glucose cotransporter 2 (SGLT2) inhibitor velagliflozin, a new drug with therapeutic potential to treat diabetes in cats","volume":"41","author":"Hoenig","year":"2018","journal-title":"J. Vet. Pharmacol. Ther"},{"key":"10.1074\/jbc.REV120.008387_bib134","doi-asserted-by":"crossref","first-page":"e30555","DOI":"10.1371\/journal.pone.0030555","article-title":"Effect of canagliflozin on renal threshold for glucose, glycemia, and body weight in normal and diabetic animal models","volume":"7","author":"Liang","year":"2012","journal-title":"PLoS ONE"},{"key":"10.1074\/jbc.REV120.008387_bib135","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.123130","article-title":"SGLT2 inhibition reprograms systemic metabolism via FGF21-dependent and -independent mechanisms","volume":"4","author":"Osataphan","year":"2019","journal-title":"JCI Insight"},{"key":"10.1074\/jbc.REV120.008387_bib136","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.2337\/dc16-0542","article-title":"Can a shift in fuel energetics explain the beneficial cardiorenal outcomes in the EMPA-REG OUTCOME study? A unifying hypothesis","volume":"39","author":"Mudaliar","year":"2016","journal-title":"Diabetes Care"},{"key":"10.1074\/jbc.REV120.008387_bib137","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.2337\/dc16-0330","article-title":"CV protection in the EMPA-REG OUTCOME trial: a \u201cthrifty substrate\u201d hypothesis","volume":"39","author":"Ferrannini","year":"2016","journal-title":"Diabetes Care"},{"key":"10.1074\/jbc.REV120.008387_bib138","doi-asserted-by":"crossref","first-page":"186","DOI":"10.3389\/fcvm.2019.00186","article-title":"SGLT2 inhibitors play a salutary role in heart failure via modulation of the mitochondrial function","volume":"6","author":"Maejima","year":"2019","journal-title":"Front. Cardiovasc. Med"},{"key":"10.1074\/jbc.REV120.008387_bib139","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1093\/cvr\/cvz045","article-title":"Increased ketone body oxidation provides additional energy for the failing heart without improving cardiac efficiency","volume":"115","author":"Ho","year":"2019","journal-title":"Cardiovasc. Res"},{"key":"10.1074\/jbc.REV120.008387_bib140","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/j.jacbts.2018.07.006","article-title":"Empagliflozin increases cardiac energy production in diabetes: novel translational insights into the heart failure benefits of SGLT2 inhibitors","volume":"3","author":"Verma","year":"2018","journal-title":"JACC Basic Transl. Sci"},{"key":"10.1074\/jbc.REV120.008387_bib141","doi-asserted-by":"crossref","first-page":"2127","DOI":"10.1038\/s41467-020-15983-6","article-title":"SGLT2 inhibition modulates NLRP3 inflammasome activity via ketones and insulin in diabetes with cardiovascular disease","volume":"11","author":"Kim","year":"2020","journal-title":"Nat. Commun"},{"key":"10.1074\/jbc.REV120.008387_bib142","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1016\/j.cardfail.2015.04.014","article-title":"The importance of NLRP3 inflammasome in heart failure","volume":"21","author":"Butts","year":"2015","journal-title":"J. Card. Fail"},{"key":"10.1074\/jbc.REV120.008387_bib143","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.cmet.2016.07.018","article-title":"Empagliflozin's fuel hypothesis: not so soon","volume":"24","author":"Lopaschuk","year":"2016","journal-title":"Cell Metab"},{"key":"10.1074\/jbc.REV120.008387_bib144","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1002\/oby.22748","article-title":"Efficacy and safety of ertugliflozin in patients with overweight and obesity with type 2 diabetes mellitus","volume":"28","author":"Heymsfield","year":"2020","journal-title":"Obesity (Silver Spring)"},{"key":"10.1074\/jbc.REV120.008387_bib145","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1080\/03007995.2020.1760227","article-title":"Efficacy and safety of ertugliflozin in Hispanic\/Latino patients with type 2 diabetes mellitus","volume":"36","author":"Liu","year":"2020","journal-title":"Curr. Med. Res. Opin"},{"key":"10.1074\/jbc.REV120.008387_bib146","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1080\/03007995.2020.1760228","article-title":"Efficacy and safety of ertugliflozin across racial groups in patients with type 2 diabetes mellitus","volume":"36","author":"Liu","year":"2020","journal-title":"Curr. Med. Res. Opin"},{"key":"10.1074\/jbc.REV120.008387_bib147","doi-asserted-by":"crossref","first-page":"e14360","DOI":"10.14814\/phy2.14360","article-title":"Osmotic diuresis by SGLT2 inhibition stimulates vasopressin-induced water reabsorption to maintain body fluid volume","volume":"8","author":"Masuda","year":"2020","journal-title":"Physiol. Rep"},{"key":"10.1074\/jbc.REV120.008387_bib148","doi-asserted-by":"crossref","first-page":"e004007","DOI":"10.1161\/JAHA.116.004007","article-title":"Effect of sodium-glucose cotransport-2 inhibitors on blood pressure in people with type 2 diabetes mellitus: a systematic review and meta-analysis of 43 randomized control trials with 22 528 patients","volume":"6","author":"Mazidi","year":"2017","journal-title":"J. Am. Heart Assoc"},{"key":"10.1074\/jbc.REV120.008387_bib149","doi-asserted-by":"crossref","first-page":"e005686","DOI":"10.1161\/JAHA.117.005686","article-title":"Effects of sodium-glucose cotransporter 2 inhibitors on 24-hour ambulatory blood pressure: a systematic review and meta-analysis","volume":"6","author":"Baker","year":"2017","journal-title":"J. Am. Heart Assoc"},{"key":"10.1074\/jbc.REV120.008387_bib150","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1016\/j.jash.2014.02.003","article-title":"Blood pressure effects of sodium-glucose co-transport 2 (SGLT2) inhibitors","volume":"8","author":"Oliva","year":"2014","journal-title":"J. Am. Soc. Hypertens"},{"key":"10.1074\/jbc.REV120.008387_bib151","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1111\/jch.12747","article-title":"Reductions in mean 24-hour ambulatory blood pressure after 6-week treatment with canagliflozin in patients with type 2 diabetes mellitus and hypertension","volume":"18","author":"Townsend","year":"2016","journal-title":"J. Clin. Hypertens. (Greenwich)"},{"key":"10.1074\/jbc.REV120.008387_bib152","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.jacbts.2019.11.007","article-title":"SGLT2 inhibitor-induced sympathoinhibition: a novel mechanism for cardiorenal protection","volume":"5","author":"Herat","year":"2020","journal-title":"JACC Basic Transl. Sci"},{"key":"10.1074\/jbc.REV120.008387_bib153","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1111\/dom.14025","article-title":"Effectiveness of sodium-glucose co-transporter-2 inhibitors on ischaemic heart disease","volume":"22","author":"Shen","year":"2020","journal-title":"Diabetes Obes. Metab"},{"key":"10.1074\/jbc.REV120.008387_bib154","doi-asserted-by":"crossref","first-page":"267","DOI":"10.14740\/jocmr3761","article-title":"Renoprotective effects of additional SGLT2 inhibitor therapy in patients with type 2 diabetes mellitus and chronic kidney disease stages 3b\u20134: a real world report from a Japanese specialized diabetes care center","volume":"11","author":"Sugiyama","year":"2019","journal-title":"J. Clin. Med. Res"},{"key":"10.1074\/jbc.REV120.008387_bib155","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1111\/jdi.12971","article-title":"Empagliflozin and kidney outcomes in Asian patients with type 2 diabetes and established cardiovascular disease: results from the EMPA-REG OUTCOME((R)) trial","volume":"10","author":"Kadowaki","year":"2019","journal-title":"J. Diabetes Investig"},{"key":"10.1074\/jbc.REV120.008387_bib156","doi-asserted-by":"crossref","first-page":"466","DOI":"10.14740\/jocmr3419w","article-title":"Impact of dapagliflozin therapy on renal protection and kidney morphology in patients with uncontrolled type 2 diabetes mellitus","volume":"10","author":"Sugiyama","year":"2018","journal-title":"J. Clin. Med. Res"},{"key":"10.1074\/jbc.REV120.008387_bib157","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.1093\/ndt\/gfx350","article-title":"Effects of the sodium-glucose co-transporter 2 inhibitor dapagliflozin in patients with type 2 diabetes and Stages 3b\u20134 chronic kidney disease","volume":"33","author":"Dekkers","year":"2018","journal-title":"Nephrol. Dial. Transplant"},{"key":"10.1074\/jbc.REV120.008387_bib158","doi-asserted-by":"crossref","first-page":"7238","DOI":"10.1038\/s41598-020-64380-y","article-title":"Empagliflozin attenuates acute kidney injury after myocardial infarction in diabetic rats","volume":"10","author":"Kuno","year":"2020","journal-title":"Sci. Rep"},{"key":"10.1074\/jbc.REV120.008387_bib159","doi-asserted-by":"crossref","first-page":"5237","DOI":"10.3390\/ijms20205237","article-title":"The SGLT2 inhibitor canagliflozin prevents carcinogenesis in a mouse model of diabetes and non-alcoholic steatohepatitis-related hepatocarcinogenesis: association with SGLT2 expression in hepatocellular carcinoma","volume":"20","author":"Jojima","year":"2019","journal-title":"Int. J. Mol. Sci"},{"key":"10.1074\/jbc.REV120.008387_bib160","doi-asserted-by":"crossref","first-page":"3390","DOI":"10.3390\/molecules24183390","article-title":"Trilobatin, a novel SGLT1\/2 inhibitor, selectively induces the proliferation of human hepatoblastoma cells","volume":"24","author":"Wang","year":"2019","journal-title":"Molecules"},{"key":"10.1074\/jbc.REV120.008387_bib161","doi-asserted-by":"crossref","first-page":"1712","DOI":"10.1002\/ijc.31193","article-title":"Sodium glucose cotransporter 2 inhibitor canagliflozin attenuates liver cancer cell growth and angiogenic activity by inhibiting glucose uptake","volume":"142","author":"Kaji","year":"2018","journal-title":"Int. J. Cancer"},{"key":"10.1074\/jbc.REV120.008387_bib162","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1208\/s12249-017-0874-2","article-title":"Magnetic nanoparticles for the delivery of dapagliflozin to hypoxic tumors: physicochemical characterization and cell studies","volume":"19","author":"Angelopoulou","year":"2018","journal-title":"AAPS PharmSciTech"},{"key":"10.1074\/jbc.REV120.008387_bib163","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1016\/j.molmet.2016.08.014","article-title":"The diabetes medication Canagliflozin reduces cancer cell proliferation by inhibiting mitochondrial complex-I supported respiration","volume":"5","author":"Villani","year":"2016","journal-title":"Mol. Metab"},{"key":"10.1074\/jbc.REV120.008387_bib164","doi-asserted-by":"crossref","first-page":"3737","DOI":"10.12659\/MSM.902530","article-title":"Therapeutic effect of sodium glucose co-transporter 2 inhibitor dapagliflozin on renal cell carcinoma","volume":"23","author":"Kuang","year":"2017","journal-title":"Med. Sci. Monit"},{"key":"10.1074\/jbc.REV120.008387_bib165","doi-asserted-by":"crossref","first-page":"255-OR","DOI":"10.2337\/db18-255-OR","article-title":"SGLT2 inhibitor ipragliflozin induces breast cancer apoptosis via membrane hyperpolarization and mitochondria dysfunction","volume":"67","author":"Komatsu","year":"2018","journal-title":"Diabetes"},{"key":"10.1074\/jbc.REV120.008387_bib166","doi-asserted-by":"crossref","first-page":"647.48","DOI":"10.1096\/fasebj.2019.33.1_supplement.647.48","article-title":"The effect of sodium glucose transporter 2 inhibitors on proliferation and growth factor signaling pathways in triple negative breast cancer","volume":"33","author":"Ware","year":"2019","journal-title":"FASEB J"},{"key":"10.1074\/jbc.REV120.008387_bib167","doi-asserted-by":"crossref","first-page":"e0218126","DOI":"10.1371\/journal.pone.0218126","article-title":"Obesity-associated, but not obesity-independent, tumors respond to insulin by increasing mitochondrial glucose oxidation","volume":"14","author":"Rabin-Court","year":"2019","journal-title":"PLoS ONE"},{"key":"10.1074\/jbc.REV120.008387_bib168","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/s40170-019-0203-1","article-title":"SGLT2 inhibition slows tumor growth in mice by reversing hyperinsulinemia","volume":"7","author":"Nasiri","year":"2019","journal-title":"Cancer Metab"},{"key":"10.1074\/jbc.REV120.008387_bib169","doi-asserted-by":"crossref","first-page":"2362","DOI":"10.1038\/s41598-018-19658-7","article-title":"Canagliflozin, an SGLT2 inhibitor, attenuates the development of hepatocellular carcinoma in a mouse model of human NASH","volume":"8","author":"Shiba","year":"2018","journal-title":"Sci. Rep"},{"key":"10.1074\/jbc.REV120.008387_bib170","doi-asserted-by":"crossref","first-page":"58353","DOI":"10.18632\/oncotarget.16874","article-title":"Preventive effects of the sodium glucose cotransporter 2 inhibitor tofogliflozin on diethylnitrosamine-induced liver tumorigenesis in obese and diabetic mice","volume":"8","author":"Obara","year":"2017","journal-title":"Oncotarget"},{"key":"10.1074\/jbc.REV120.008387_bib171","doi-asserted-by":"crossref","first-page":"eaat5933","DOI":"10.1126\/scitranslmed.aat5933","article-title":"Sodium-glucose transporter 2 is a diagnostic and therapeutic target for early-stage lung adenocarcinoma","volume":"10","author":"Scafoglio","year":"2018","journal-title":"Sci. Transl. Med"},{"key":"10.1074\/jbc.REV120.008387_bib172","doi-asserted-by":"crossref","first-page":"1860","DOI":"10.1016\/j.celrep.2019.07.027","article-title":"p63 and SOX2 dictate glucose reliance and metabolic vulnerabilities in squamous cell carcinomas","volume":"28","author":"Hsieh","year":"2019","journal-title":"Cell Rep"},{"key":"10.1074\/jbc.REV120.008387_bib173","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1111\/j.1349-7006.2001.tb01175.x","article-title":"SGLT gene expression in primary lung cancers and their metastatic lesions","volume":"92","author":"Ishikawa","year":"2001","journal-title":"Jpn. J. Cancer Res"},{"key":"10.1074\/jbc.REV120.008387_bib174","first-page":"199","article-title":"MicroRNA-296, a suppressor non-coding RNA, downregulates SGLT2 expression in lung cancer","volume":"54","author":"Zhang","year":"2019","journal-title":"Int. J. Oncol"},{"key":"10.1074\/jbc.REV120.008387_bib175","doi-asserted-by":"crossref","first-page":"E4111","DOI":"10.1073\/pnas.1511698112","article-title":"Functional expression of sodium-glucose transporters in cancer","volume":"112","author":"Scafoglio","year":"2015","journal-title":"Proc. Natl. Acad. Sci. U. S. A"},{"key":"10.1074\/jbc.REV120.008387_bib176","doi-asserted-by":"crossref","first-page":"3171","DOI":"10.2147\/CMAR.S195424","article-title":"SLC5A1 promotes growth and proliferation of pancreatic carcinoma via glucose-dependent AMPK\/mTOR signaling","volume":"11","author":"Gao","year":"2019","journal-title":"Cancer Manag. Res"},{"key":"10.1074\/jbc.REV120.008387_bib177","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1080\/13813450801954451","article-title":"Hyper-insulinaemia and cancer, meta-analyses of epidemiological studies","volume":"114","author":"Pisani","year":"2008","journal-title":"Arch. Physiol. Biochem"},{"key":"10.1074\/jbc.REV120.008387_bib178","doi-asserted-by":"crossref","first-page":"333","DOI":"10.2174\/15680266113136660067","article-title":"Use of insulin and insulin analogs and risk of cancer\u2014systematic review and meta-analysis of observational studies","volume":"8","author":"Karlstad","year":"2013","journal-title":"Curr. Drug. Saf"},{"key":"10.1074\/jbc.REV120.008387_bib179","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1111\/j.1749-6632.1996.tb16235.x","article-title":"Insulin receptors in breast cancer","volume":"784","author":"Belfiore","year":"1996","journal-title":"Ann. N. Y. Acad. Sci"},{"key":"10.1074\/jbc.REV120.008387_bib180","doi-asserted-by":"crossref","first-page":"37497","DOI":"10.18632\/oncotarget.26490","article-title":"Epithelial insulin receptor expression-prognostic relevance in colorectal cancer","volume":"9","author":"Heckl","year":"2018","journal-title":"Oncotarget"},{"key":"10.1074\/jbc.REV120.008387_bib181","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1172\/JCI114868","article-title":"Elevated insulin receptor content in human breast cancer","volume":"86","author":"Papa","year":"1990","journal-title":"J. Clin. Invest"},{"key":"10.1074\/jbc.REV120.008387_bib182","doi-asserted-by":"crossref","first-page":"3278","DOI":"10.1128\/MCB.19.5.3278","article-title":"Insulin receptor isoform A, a newly recognized, high-affinity insulin-like growth factor II receptor in fetal and cancer cells","volume":"19","author":"Frasca","year":"1999","journal-title":"Mol. Cell Biol"},{"key":"10.1074\/jbc.REV120.008387_bib183","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1002\/pros.20852","article-title":"Insulin receptor expression by human prostate cancers","volume":"69","author":"Cox","year":"2009","journal-title":"Prostate"},{"key":"10.1074\/jbc.REV120.008387_bib184","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1002\/path.4892","article-title":"High expression of insulin receptor on tumour-associated blood vessels in invasive bladder cancer predicts poor overall and progression-free survival","volume":"242","author":"Roudnicky","year":"2017","journal-title":"J. Pathol"},{"key":"10.1074\/jbc.REV120.008387_bib185","doi-asserted-by":"crossref","first-page":"3974","DOI":"10.1158\/0008-5472.CAN-12-3824","article-title":"Mitogenic insulin receptor-A is overexpressed in human hepatocellular carcinoma due to EGFR-mediated dysregulation of RNA splicing factors","volume":"73","author":"Chettouh","year":"2013","journal-title":"Cancer Res"},{"key":"10.1074\/jbc.REV120.008387_bib186","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1007\/s10120-019-00964-6","article-title":"The expression of the insulin receptor in gastric cancer correlates with the HER2 status and may have putative therapeutic implications","volume":"22","author":"Heckl","year":"2019","journal-title":"Gastric Cancer"},{"key":"10.1074\/jbc.REV120.008387_bib187","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/j.ejps.2016.08.025","article-title":"Sodium glucose cotransporter 2 (SGLT2) inhibitors: current status and future perspective","volume":"93","author":"Madaan","year":"2016","journal-title":"Eur. J. Pharm. Sci"},{"key":"10.1074\/jbc.REV120.008387_bib188","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1007\/s12325-015-0234-0","article-title":"Pharmacokinetics, pharmacodynamics, and safety of canagliflozin in Japanese patients with type 2 diabetes mellitus","volume":"32","author":"Iijima","year":"2015","journal-title":"Adv. Ther"},{"key":"10.1074\/jbc.REV120.008387_bib189","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.2337\/dc11-1926","article-title":"Dose-ranging effects of canagliflozin, a sodium-glucose cotransporter 2 inhibitor, as add-on to metformin in subjects with type 2 diabetes","volume":"35","author":"Rosenstock","year":"2012","journal-title":"Diabetes Care"},{"key":"10.1074\/jbc.REV120.008387_bib190","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1016\/S0140-6736(13)60683-2","article-title":"Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52 week results from a randomised, double-blind, phase 3 non-inferiority trial","volume":"382","author":"Cefalu","year":"2013","journal-title":"Lancet"},{"key":"10.1074\/jbc.REV120.008387_bib191","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1310\/hpj4907-647","article-title":"Dapagliflozin","volume":"49","author":"Cada","year":"2014","journal-title":"Hosp. Pharm"},{"key":"10.1074\/jbc.REV120.008387_bib192","doi-asserted-by":"crossref","first-page":"2217","DOI":"10.2337\/dc10-0612","article-title":"Dapagliflozin monotherapy in type 2 diabetic patients with inadequate glycemic control by diet and exercise: a randomized, double-blind, placebo-controlled, phase 3 trial","volume":"33","author":"Ferrannini","year":"2010","journal-title":"Diabetes Care"},{"key":"10.1074\/jbc.REV120.008387_bib193","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1111\/j.1742-1241.2012.02911.x","article-title":"Dapagliflozin, metformin XR, or both: initial pharmacotherapy for type 2 diabetes, a randomised controlled trial","volume":"66","author":"Henry","year":"2012","journal-title":"Int. J. Clin. Pract"},{"key":"10.1074\/jbc.REV120.008387_bib194","doi-asserted-by":"crossref","first-page":"50","DOI":"10.2152\/jmi.64.50","article-title":"Comparison of the efficacy and safety of 10-mg empagliflozin every day versus every other day in Japanese patients with type 2 diabetes mellitus: a pilot trial","volume":"64","author":"Obata","year":"2017","journal-title":"J. Med. Invest"},{"key":"10.1074\/jbc.REV120.008387_bib195","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1111\/dom.12185","article-title":"Efficacy and safety of empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, as add-on to metformin in type 2 diabetes with mild hyperglycaemia","volume":"15","author":"Rosenstock","year":"2013","journal-title":"Diabetes Obes. Metab"},{"key":"10.1074\/jbc.REV120.008387_bib196","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1111\/dom.12469","article-title":"Efficacy and safety of empagliflozin twice daily versus once daily in patients with type 2 diabetes inadequately controlled on metformin: a 16-week, randomized, placebo-controlled trial","volume":"17","author":"Ross","year":"2015","journal-title":"Diabetes Obes. Metab"}],"container-title":["Journal of Biological Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0021925817497808?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0021925817497808?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1074\/jbc.REV120.008387","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,31]],"date-time":"2021-12-31T11:40:22Z","timestamp":1640950822000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0021925817497808"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10]]},"references-count":196,"journal-issue":{"issue":"42","published-print":{"date-parts":[[2020,10]]}},"alternative-id":["S0021925817497808"],"URL":"https:\/\/doi.org\/10.1074\/jbc.rev120.008387","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.738504708.793577720","asserted-by":"object"}]},"ISSN":["0021-9258"],"issn-type":[{"value":"0021-9258","type":"print"}],"subject":[],"published":{"date-parts":[[2020,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Sodium-glucose cotransporter-2 inhibitors: Understanding the mechanisms for therapeutic promise and persisting risks","name":"articletitle","label":"Article Title"},{"value":"Journal of Biological Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1074\/jbc.REV120.008387","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Perry and Shulman.","name":"copyright","label":"Copyright"}]}}